| 2.71 -0.18 (-6.23%) | 12-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.45  |
1-year : | 4.06 |
| Resists | First : | 2.95 |
Second : | 3.48 |
| Pivot price | 2.82  |
|||
| Supports | First : | 2.1 |
Second : | 1.75 |
| MAs | MA(5) : | 2.96 |
MA(20) : | 2.7 |
| MA(100) : | 3.13 |
MA(250) : | 106.53 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 52.6 |
D(3) : | 60.6 |
| RSI | RSI(14): 47.3 |
|||
| 52-week | High : | 608 | Low : | 2.1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SBFM ] has closed above bottom band by 40.5%. Bollinger Bands are 5.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.92 - 2.94 | 2.94 - 2.95 |
| Low: | 2.66 - 2.68 | 2.68 - 2.69 |
| Close: | 2.68 - 2.71 | 2.71 - 2.73 |
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Tue, 10 Dec 2024
Sunshine Biopharma’s PLpro inhibitor shows activity in SARS-CoV-2 - BioWorld Online
Mon, 09 Dec 2024
Sunshine Biopharma's Novel COVID-19 Oral Treatment Shows Breakthrough Antiviral Activity in Preclinical Study - StockTitan
Mon, 09 Dec 2024
Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus - Yahoo Finance
Wed, 04 Dec 2024
Sunshine Biopharma Launches Generic Allergy Drug in $1.3B Global Bilastine Market - StockTitan
Fri, 22 Nov 2024
Sunshine Biopharma Launches New Generic Drug in $933M Growing Market - StockTitan
Wed, 06 Nov 2024
Sunshine Biopharma Q3 Revenue Surges 42% to $8.4M Despite Widening Losses - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 1.8 (%) |
| Shares Short | 234 (K) |
| Shares Short P.Month | 322 (K) |
| EPS | -127.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.52 |
| Profit Margin | -12.9 % |
| Operating Margin | -13.2 % |
| Return on Assets (ttm) | -10.8 % |
| Return on Equity (ttm) | -18 % |
| Qtrly Rev. Growth | 41.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 16.47 |
| EBITDA (p.s.) | -2.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.03 |
| PEG Ratio | 0 |
| Price to Book value | 0.21 |
| Price to Sales | 0.16 |
| Price to Cash Flow | -0.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|